Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis | Zendy

Antonino Catalano | Zendy; N. Morabito | Zendy; Giorgio Basile | Zendy; Santa Brancatelli | Zendy; Domenico Cucinotta | Zendy; Antonino Lasco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis

Author(s) -

Antonino Catalano,

N. Morabito,

Giorgio Basile,

Santa Brancatelli,

Domenico Cucinotta,

Antonino Lasco

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-4039

Subject(s) - sclerostin , zoledronic acid , medicine , endocrinology , bone remodeling , bone resorption , osteoporosis , n terminal telopeptide , placebo , osteocalcin , alkaline phosphatase , chemistry , wnt signaling pathway , biochemistry , pathology , alternative medicine , gene , enzyme

Sclerostin is a circulating inhibitor of the Wnt-signaling pathway produced by osteocytes, which acts as a negative regulator of bone formation. Effects of zoledronic acid on sclerostin serum levels in postmenopausal osteoporosis are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research